Maureen Riordan
Senior Deals Analyst

Latest From Maureen Riordan
Deals In Depth: March 2021
BridgeBio Pharma’s affiliate QED Therapeutics granted and Helsinn Group exclusive global rights (excluding Greater China) to the FGFR1-3 inhibitor infigratinib in oncology and all other indications except skeletal dysplasias (including achondroplasia). BridgeBio could see up to $2.45bn in payments from the deal, including over $100m in up-front, regulatory, and launch payments, and the remainder in sales milestones. In the month’s top M&A, Amgen entered into an agreement to acquire fellow public biotech Five Prime Therapeutics for about $1.9bn, gaining Phase III-ready bemarituzumab for frontline advanced gastric or gastroesophageal junction cancer.
Dealmaking Quarterly Statistics, Q4 2020
During Q4, medical device company M&A values reached $5.7bn, while in vitro diagnostic firms and research tools players completed M&A activity that totaled $3.3bn.
Deals In Depth: February 2021
Molecular Templates penned a research collaboration with Bristol Myers Squibb to discover and develop multiple therapies designed for specific oncology targets using Molecular’s next-generation engineered toxin body platform. BMS paid $70m up front and could shell out development and regulatory milestones up to $874.5m and $450m upon the achievement of certain sales milestones. ICON entered into a definitive agreement to acquire fellow public CRO PRA Health Sciences in a 48% cash and 52% stock transaction valued at approximately $12bn. Financing reached $11.4bn in biopharma, $1.2bn in device, and $1.5bn in diagnostics.
Deals In Depth: January 2021
BeiGene and Novartis penned a potential $2.2bn collaboration for the development, manufacture, and commercialization of BeiGene’s humanized IgG4 anti-PD-1 monoclonal antibody tislelizumab in the US, Canada, Mexico, member countries of the EU, the UK, Norway, Switzerland, Iceland, Liechtenstein, Russia, and Japan. Steris entered into a definitive agreement to acquire Cantel Medical, a global provider of infection prevention products and services primarily to endoscopy and dental customers. The total enterprise value of the deal is estimated at $4.6bn. Financing reached $10.5bn in biopharma, $984m in device, and $2.7bn in diagnostics.
Financing: 2020 Ends On A High Note For Medtech
During Q4, device company fundraising totaled $4.2bn; while in vitro diagnostic firms and research tools players raised $6.1bn.
Dealmaking Quarterly Statistics, Q4 2020
During Q4, biopharma merger and acquisition value reached $73.9bn and drew in $54.5bn in potential deal value from alliances. Device company M&A values reached $5.7bn, while in vitro diagnostic firms and research tools players completed M&A activity that totaled $3.3bn.